Sumatriptan intranasal - Aegis Therapeutics

Drug Profile

Sumatriptan intranasal - Aegis Therapeutics

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Aegis Therapeutics
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Migraine

Most Recent Events

  • 30 Aug 2016 Aegis Therapeutics receives patent for for fast acting migraine nasal spray treatment in Hong Kong .
  • 17 Mar 2016 Aegis Therapeutics receives patent allowance for Fast acting migraine nasal spray treatment in USA
  • 11 Aug 2015 Aegis therapeutics has patent protection for non-invasive delivery of intranasal sumatriptan for Migraine in China and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top